Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.

Ruff P, Van Cutsem E, Lakomy R, Prausova J, van Hazel GA, Moiseyenko VM, Soussan-Lazard K, Dochy E, Magherini E, Macarulla T, Papamichael D.

J Geriatr Oncol. 2018 Jan;9(1):32-39. doi: 10.1016/j.jgo.2017.07.010. Epub 2017 Aug 12.

PMID:
28807738
2.

Reply to E.C. Harrold et al and A.O. Ayoola et al.

van Hazel GA, Gibbs P.

J Clin Oncol. 2016 Dec;34(34):4194-4195. Epub 2016 Sep 30. No abstract available.

PMID:
27621391
3.

SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.

van Hazel GA, Heinemann V, Sharma NK, Findlay MP, Ricke J, Peeters M, Perez D, Robinson BA, Strickland AH, Ferguson T, Rodríguez J, Kröning H, Wolf I, Ganju V, Walpole E, Boucher E, Tichler T, Shacham-Shmueli E, Powell A, Eliadis P, Isaacs R, Price D, Moeslein F, Taieb J, Bower G, Gebski V, Van Buskirk M, Cade DN, Thurston K, Gibbs P.

J Clin Oncol. 2016 May 20;34(15):1723-31. doi: 10.1200/JCO.2015.66.1181. Epub 2016 Feb 22. Erratum in: J Clin Oncol. 2016 Nov 20;34(33):4059.

PMID:
26903575
4.

Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma.

Gibbs P, Do C, Lipton L, Cade DN, Tapner MJ, Price D, Bower GD, Dowling R, Lichtenstein M, van Hazel GA.

BMC Cancer. 2015 Oct 26;15:802. doi: 10.1186/s12885-015-1822-8.

6.

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.

Ruff P, Ferry DR, Lakomỳ R, Prausová J, Van Hazel GA, Hoff PM, Cunningham D, Arnold D, Schmoll HJ, Moiseyenko VM, McKendrick JJ, Ten Tije AJ, Vishwanath RL, Bhargava P, Chevalier S, Macarulla T, Van Cutsem E.

Eur J Cancer. 2015 Jan;51(1):18-26. doi: 10.1016/j.ejca.2014.10.019. Epub 2014 Nov 14.

7.

PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.

Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA; NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group.

Clin Cancer Res. 2014 Feb 1;20(3):744-53. doi: 10.1158/1078-0432.CCR-13-0606. Epub 2013 Nov 11.

8.

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.

Tabernero J, Van Cutsem E, Lakomý R, Prausová J, Ruff P, van Hazel GA, Moiseyenko VM, Ferry DR, McKendrick JJ, Soussan-Lazard K, Chevalier S, Allegra CJ.

Eur J Cancer. 2014 Jan;50(2):320-31. doi: 10.1016/j.ejca.2013.09.013. Epub 2013 Oct 16.

9.

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial.

Tebbutt NC, Parry MM, Zannino D, Strickland AH, Van Hazel GA, Pavlakis N, Ganju V, Mellor D, Dobrovic A, Gebski VJ; Australasian Gastro-Intestinal Trials Group (AGITG).

Br J Cancer. 2013 Mar 5;108(4):771-4. doi: 10.1038/bjc.2013.41. Epub 2013 Feb 14.

10.

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C.

J Clin Oncol. 2012 Oct 1;30(28):3499-506. Epub 2012 Sep 4.

PMID:
22949147
11.

The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.

Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro J, Porter IW, Hruby G, Horvath L, Bydder S, Underhill C, Harvey J, Gebski VJ; Australasian Gastro-Intestinal Trials Group.

Br J Cancer. 2012 Jan 3;106(1):61-9. doi: 10.1038/bjc.2011.526. Epub 2011 Dec 1.

12.

Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.

Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC.

Ann Oncol. 2012 Jun;23(6):1531-6. doi: 10.1093/annonc/mdr488. Epub 2011 Oct 29.

PMID:
22039086
13.

Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].

Clarke SJ, Yip S, Brown C, van Hazel GA, Ransom DT, Goldstein D, Jeffrey GM, Tebbutt NC, Buck M, Lowenthal RM, Boland A, Gebski V, Zalcberg J, Simes RJ; Australasian Gastro-Intestinal Trials Group.

Eur J Cancer. 2011 Aug;47(12):1826-36. doi: 10.1016/j.ejca.2011.04.024. Epub 2011 Jun 12. Erratum in: Eur J Cancer. 2012 Feb;48(3):407.

PMID:
21665462
14.

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.

Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ.

J Clin Oncol. 2010 Jul 1;28(19):3191-8. doi: 10.1200/JCO.2009.27.7723. Epub 2010 Jun 1.

PMID:
20516443
15.

Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.

van Hazel GA, Pavlakis N, Goldstein D, Olver IN, Tapner MJ, Price D, Bower GD, Briggs GM, Rossleigh MA, Taylor DJ, George J.

J Clin Oncol. 2009 Sep 1;27(25):4089-95. doi: 10.1200/JCO.2008.20.8116. Epub 2009 Aug 3.

PMID:
19652069
16.

Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.

Sharma RA, Van Hazel GA, Morgan B, Berry DP, Blanshard K, Price D, Bower G, Shannon JA, Gibbs P, Steward WP.

J Clin Oncol. 2007 Mar 20;25(9):1099-106.

PMID:
17369573
17.

A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma.

Kefford R, Beith JM, Van Hazel GA, Millward M, Trotter JM, Wyld DK, Kusic R, Shreeniwas R, Morganti A, Ballmer A, Segal E, Nayler O, Clozel M.

Invest New Drugs. 2007 Jun;25(3):247-52. Epub 2006 Oct 5.

PMID:
17021960
18.

An open multicentre study of tropisetron for cisplatin-induced nausea and vomiting.

Olver IN, Craft PS, Clingan PR, Kearsley JH, Planner RS, van Hazel GA, Bell DR, Adena MR, Hall BE, Pearson LL.

Med J Aust. 1996 Mar 18;164(6):337-40.

PMID:
8606657
19.

Predicting relapse in stage I non-seminomatous germ cell tumours of the testis.

Dewar JM, Spagnolo DV, Jamrozik KD, van Hazel GA, Byrne MJ.

Lancet. 1987 Feb 21;1(8530):454. No abstract available.

PMID:
2880250
20.

Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.

van Hazel GA, Scott M, Rubin J, Moertel CG, Eagan RT, O'Connell MJ, Kovach JS.

Cancer Treat Rep. 1983 Sep;67(9):805-10.

PMID:
6411337
21.

Treatment of metastatic carcinoid tumor with dactinomycin or dacarbazine.

van Hazel GA, Rubin J, Moertel CG.

Cancer Treat Rep. 1983 Jun;67(6):583-5.

PMID:
6861165
22.

A phase II study of 6-diazo-5-oxo-L-norleucine (DON, NSC-7365) in advanced large bowel carcinoma.

Rubin J, Sorensen S, Schutt AJ, van Hazel GA, O'Connell MJ, Moertel CG.

Am J Clin Oncol. 1983 Jun;6(3):325-6. No abstract available.

PMID:
6846250
23.

The effect of CNS metastases on the survival of patients with small cell cancer of the lung.

van Hazel GA, Scott M, Eagan RT.

Cancer. 1983 Mar 1;51(5):933-7.

PMID:
6295619
24.

A phase II study of aziridinylbenzoquinone (AZQ) in advanced large bowel carcinoma.

Rubin J, van Hazel GA, Schutt AJ, Moertel CG, O'Connell MJ.

Am J Clin Oncol. 1982 Oct;5(5):539-40.

PMID:
7180832
25.

Pharmacokinetics of mitomycin C in rabbit and human.

van Hazel GA, Kovach JS.

Cancer Chemother Pharmacol. 1982;8(2):189-92.

PMID:
6809356

Supplemental Content

Loading ...
Support Center